Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 monthsPresented nonclinical prostate cancer data at ASCO GU Cancers …